May 2nd, 2016
Posted by Shane Climie, Ph.D.
Researchers in the field of immuno-oncology have achieved remarkable success over the past five years. The ability to boost the immune system to attack cancer using a variety of biotechnology-derived approaches has led to the successful treatment of thousands of patients with advanced melanoma, lung cancer, and various types of leukemia. The success of these approaches has extended the lives of many patients, a significant number of whom have seemingly been cured. All of this has created a great deal of excitement and optimism among patients, researchers, and physicians after many years of frustration, false starts, and failed trials.